Expand ARGX Menu
ARGX MENU

ARGX Latest Press Releases

-- May 28, 2026 --

argenx to Host Myositis R&D Webinar on June 23, 2026 Globe Newswire 1:00 AM

-- May 27, 2026 --

argenx to Present at Upcoming Investor Conferences Globe Newswire 1:00 AM

-- May 18, 2026 --

The Biology Came First. Business Wire 8:34 AM

-- May 8, 2026 --

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG Globe Newswire 5:20 PM

-- May 7, 2026 --

argenx Reports First Quarter 2026 Financial Results and Provides Business Update Globe Newswire 1:00 AM

-- May 6, 2026 --

argenx to Present at BofA Securities 2026 Health Care Conference Globe Newswire 4:30 PM
argenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive Officer Globe Newswire 4:01 PM

-- April 30, 2026 --

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026 Globe Newswire 1:00 AM

-- April 18, 2026 --

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP Globe Newswire 1:00 AM

-- March 20, 2026 --

argenx announces Annual General Meeting of Shareholders on May 6, 2026 Globe Newswire 4:01 PM

-- March 6, 2026 --

argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline Globe Newswire 1:00 AM

-- February 26, 2026 --

argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update Globe Newswire 1:00 AM
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis Globe Newswire 12:30 AM

-- February 23, 2026 --

argenx to Present at TD Cowen 46th Annual Healthcare Conference Globe Newswire 1:00 AM

-- February 19, 2026 --

argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026 Globe Newswire 1:00 AM

-- January 13, 2026 --

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG Globe Newswire 1:00 AM

-- January 12, 2026 --

argenx Highlights 2026 Strategic Priorities Globe Newswire 1:00 AM

-- January 6, 2026 --

argenx to Present at 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 1:00 AM

-- January 5, 2026 --

argenx Announces Leadership Transition Marking Next Evolution of Growth Globe Newswire 1:00 AM
Market Data Delayed 15 Minutes